擅长:
主持多项抗癌新药的Ⅰ、Ⅱ、Ⅲ期临床研究,参与国际多中心临床研究工作40余项,目前承担多项国家、市级重大专项等课题研究,率先开展局部晚期乳腺癌光动力治疗的基础与临床研究,开辟了光动力转化医学研究新领域,并获2014年度天津科技进步三等奖。多次受邀参加国内外学术会议大会发言。国内外发表论文80余篇,主编论著1部。参与完成论著7部。培养硕士研究生10余名。
发表论文:
Ge J, Yu Y, Xin F, Yang ZJ, Zhao HM, Wang X, Tong ZS, Cao XC. Downregulation of delta-aminolevulinate dehydratase is associated with poor prognosis in patients with breast cancer.Cancer Sci. 2017 Feb 3.[Epub ahead of print]
Wang S, Li W, Wang F, Niu Y, Hao C, Wang X, He L, Tong Z. 36 cases adenoid cystic carcinoma of the breast in China: Comparison with matched grade one invasive ductal carcinoma-not otherwise specified. Pathol Res Pract. 2017 Apr;213(4):310-315.
Zhang P, Sun T, Zhang Q, Yuan Z, Jiang Z, Wang XJ, Cui S, Teng Y, Hu XC, Yang J, Pan H, Tong Z, Li H, Yao Q, Wang Y, Yin Y, Sun P, Zheng H, Cheng J, Lu J, Zhang B, Geng C, Liu J, Peng R, Yan M, Zhang S, Huang J, Tang L, Qiu R, Xu B; BG01-1323L study group. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet Oncol. 2017 Mar;18(3):371-383.
Zhang L, Wu Y, Liu F, Fu L, Tong Z. Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer. Oncotarget. 2016 Aug 9;7(32):52450-52459.
Shi YH, Dai DF, Li J, Dong YW, Jiang Y, Li HG, Gao Y, Chong CK, Li HY, Chu XQ, Yang C, Zhang Q, Tong ZS, Bai CG, Chen Y. Sulforaphane Analogues with Heterocyclic Moieties: Syntheses and Inhibitory Activities against Cancer Cell Lines. Molecules. 2016 Apr 21;21(4):514.
Zhang P, Tong Z, Tian F, Wang Y, Yang J, Li W, Di L, Liu W, Tang L, Qiu R, Xu B. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients. J Hematol Oncol. 2016 Aug 11;9(1):68.
Zhang Q, Shao Z, Shen K, Li L, Feng J, Tong Z, Gu K, Wang X, Xu B, Sun G, Chen H, Rukazenkov Y, Jiang Z.Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China. Oncotarget. 2016 Aug 30;7(35):57301-57309.
Yang M, Liu F, Higuchi K, Sawashita J, Fu X, Zhang L, Zhang L, Fu L, Tong Z, Higuchi K. Serum amyloid A expression in the breast cancer tissue is associated with poor prognosis. Oncotarget. 2016 Jun 14;7(24):35843-35852.
Xu B, Tian F, Yu J, Song Y, Shi J, Zhang B, Zhang Y, Yuan Z, Wu Q, Zhang Q, Nan K, Sun Q, Li W, Hu J, Bi J, Meng C, Dai H, Jiang H, Yue S, Cao B, Sun Y, Wang S, Tong Z, Shen P, Wu G, Tang L, Deng Y, Jia L, Shen K, Zhuang W, Xie X, Wu Y, Chen L. A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2016 Jan;38(1):23-7.
Zhao W, Wang J, Zhu B, Duan Y, Chen F, Nian W, Sun J, Zhang B, Tong Z, Chen Z. IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma. Oncol Rep. 2016 Mar;35(3):1483-92.
Jia Y, Zhou L, Tian C, Shi Y, Wang C, Tong Z. Dynamin-related protein 1 is involved in micheliolide-induced breast cancer cell death. Onco Targets Ther. 2015 Nov 16;8:3371-81.
Wang C, Ju H, Shen C, Tong Z. miR-429 mediates δ-tocotrienol-induced apoptosis in triple-negative breast cancer cells by targeting XIAP. Int J Clin Exp Med. 2015 Sep 15;8(9):15648-56.
Jia Y, Zhou L, Tian C, Shi Y, Wang C, Tong Z. Dynamin-related protein 1 is involved in micheliolide-induced breast cancer cell death. Onco Targets Ther. 2015 Nov 16;8:3371-81.
Lu N, Tong Z, Zhang M, Lu L, Cao H. Effect and mechanism of EGFR expression in macrophages on the anti-cancer effect of berberine on colorectal cancer. Zhonghua Zhong Liu Za Zhi. 2015 May;37(5):342-6.
Yuan P, Di LJ, Liu W, Wan DG, Dai H, Tong ZS, Du F, Xu BH. Phase II multi-center clinical study on using S-1 to treat advanced breast cancer after resistance to anthracycline and taxane drugs in Chinese patients. Int J Clin Exp Med. 2015 Feb 15;8(2):3072-9.
Xu B, Hu X, Jiang Z, Li H, Chen J, Cui S, Li Q, Liao N, Liu D, Liu J, Lu J, Shen K, Sun T, Teng Y, Tong Z, Wang S, Wang X, Wang X, Wang Y, Wu J, Yuan P, Zhang P, Zhang Q, Zheng H, Pang D, Ren G, Shao Z, Shen Z, Song E, Song S. National consensus in China on diagnosis and treatment of patients with advanced breast cancer. Ann Transl Med. 2015 Oct;3(17):242.
Jia Y, Zhang C, Zhou L, Xu H, Shi Y, Tong Z. Micheliolide overcomes KLF4-mediated cisplatin resistance in breast cancer cells by downregulating glutathione. Onco Targets Ther. 2015 Aug 28;8:2319-27.
Dong G, Jia Y, Wang X, Li S, Wang C, Shi Y, Tong Z. The comparison of maintenance treatment with capecitabine (CMT) and non-maintenance treatment with capecitabine (non-CMT) in patients with metastatic breast cancer. Int J Clin Exp Med. 2015 May 15;8(5):8283-7.
Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, Yin YM, Wu CP, Jiang ZF, Wang XJ, Lou GY, Liu DG, Feng JF, Luo JF, Sun K, Gu YJ, Wu J, Shao ZM. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015 Apr;16(4):436-46.
Wang F, Jia Y, Tong Z. Comparison of the clinical and prognostic features of primary breast sarcomas and malignant phyllodes tumor. Jpn J Clin Oncol. 2015 Feb;45(2):146-52.
F Wang, Y Jia, Z Tong*. Comparison of the clinical and prognostic features of primary breast sarcomas and malignant phyllodes tumor[J]. Jpn J Clin Oncol, 2015,45 (2): 146-152.
C Lu, W Wang, Y Jia, X Liu, Z Tong*, B Li*. Inhibition of AMPK/autophagy potentiates parthenolide-induced apoptosis in human breast cancer cells[J]. J Cell Biochem, 2014,115 (8): 1458-1466.
C Lu, LY Zhou, HJ Xu, XY Chen, Z Tong*, XD Liu, YS Jia, Y Chen. RIP3 overexpression sensitizes human breast cancer cells to parthenolide in vitro via intracellular ROS accumulation[J]. Acta Pharmacol Sin, 2014,35 (7): 929-936.
Lu C, Xu H, Chen X, Tong Z, Liu X, Jia Y. Irradiation after surgery for breast cancer patients with primary tumours and one to three positive axillary lymph nodes: yes or no? Curr Oncol. 2013 Dec;20(6):e585-92
Wei XQ, Li X, Xin XJ, Tong ZS, Zhang S. Clinical features and survival analysis of very young (age
预约挂号